BTIG analysts raised the price target for Liquidia Corporation (NASDAQ:LQDA) from $37 to $45 and kept a “Buy” rating. This ...

Liquidia Technologies Inc (NASDAQ:LQDA) saw its shares rise nearly 10% following news that it will begin its initial ...

Liquidia shares climbed 7.5% after disclosing that it is scheduled to make its first commercial shipment of Yutrepia inhalation powder, days after Food and Drug Administration approval. Shares were ...

Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial launch MORRISVILLE, N.C., June 02, 2025 (GLOBE ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $27.5, a high estimate of $36.00 ...

United Therapeutics Corp. (UTC) and Liquidia Technologies Inc. have been battling for close to a decade over their respective inhaled formulations ...

MannKind's pipeline and technology outweigh competitive risks and support future upside. See why we recommend a buy rating on ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Liquidia Corporation’s LQDA Yutrepia (treprostinil) ...

Triangle firm slaps feds with lawsuit over delayed product launch Morrisville firm stunned by FDA setback, vows 'quick action ...

(RTTNews) - Liquidia Corporation (LQDA), a biopharmaceutical company, announced Monday that it has made its first commercial shipment of YUTREPIA or treprostinil inhalation powder, following FDA ...

Dr. Roger Jeffs, CEO, Liquidia said: “We have moved with exceptional speed to provide a new and differentiated therapeutic alternative to the marketplace. In just over one week, our sales ...